Hemophilia Market Segmentation:
- By Product Type
- Hemophilia A
- Hemophilia B
- Inhibitors
- Von Willebrand Disease
- Others
- By Treatment Type
- On-demand
- Prophylaxis
- Extended Half-life Factors
- Hemostats
- Others
- By Therapy
- Plasma-derived Factors
- Recombinant Factors
- Non-factor Replacement
- Others
- By Age Group
- Adults (>18 years)
- Pediatric (<18 years)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
- Clinics
- Others
- By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
- North America
Frequently Asked Questions
The current market size is USD 12.1 billion in 2023
Development of extended half-life factor concentrates, Emergence of prophylaxis as standard of care, Advances in gene therapy, Expanded access in emerging markets, Increased diagnosis rates
High cost of treatment, Underdiagnosis in developing countries, Formation of inhibitors, Limited reimbursement in some markets
Hemophilia A is the leading segment due to higher patient pool and ongoing research.
Takeda, CSL Behring, Pfizer, BioMarin, Roche, Sanofi, Novo Nordisk, Bayer, Grifols, and Octapharma.
CAGR of 4.5% Market size of $17.2 billion in 2031
Novel therapies like gene therapy and RNAi, Prophylaxis becoming standard of care, Extended half-life factors requiring less frequent dosing, Improved diagnostics and screening, Rising awareness and access in emerging markets